GTC at ASH 2021

GTC is excited to be exhibiting at ASH for the first time and look forward to meeting people in person.  Our booth # 3440 and would like you will stop by and say hello.  

If you would like to schedule a meeting fill out the form below 

We have four abstracts being presented at ASH – here is the schedule below.  

1. 

2892 Bone Marrow-Based Biomarkers for Predicting aGVHD Using Targeted RNA Next Generation Sequencing and Machine Learning 

Program: Oral and Poster Abstracts 
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II 
Hematology Disease Topics & Pathways: 
Translational Research 

Sunday, December 12, 2021, 6:00 PM-8:00 PM 

Maher Albitar, MD^1*, Hong Zhang, PhD^1*, Andrew L. Pecora, MD^2*, Andrew Ip, MD, MSc³, Andre H. Goy, MD^4*, Spiraggelos Antzoulatos^1*, Ivan De Dios, BS^1*, Wanlong Ma^1*, Sukhdeep Kaur, MD^5*, Hyung C. Suh, MD, PhD^5*, Michele L. Donato, MD^5* and Scott D. Rowley, MD⁶ 

2. 

1828 Reliability of Liquid Biopsy and Next Generation Sequencing in Monitoring Residual Disease Post-Hematopoietic Stem Cell Transplant 

Program: Oral and Poster Abstracts 
Session: 723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster I 
Hematology Disease Topics & Pathways: 
Translational Research 

Saturday, December 11, 2021, 5:30 PM-7:30 PM 

Maher Albitar, MD^1*, Hong Zhang, PhD^1*, Andrew L. Pecora, MD^2*, Andrew Ip, MD, MSc³, Andre H. Goy, MD, MS^4*, Jeffrey Justin Estella, BS, MS^1*, Ivan De Dios, BS^1*, Wanlong Ma^1*, Sukhdeep Kaur, MD^5*, Hyung C. Suh, MD, PhD^5*, Michele L. Donato, MD^5* and Scott D. Rowley, MD⁶ 

3. 

2395 Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms 

Program: Oral and Poster Abstracts 
Session: 621. Lymphomas: Translational—Molecular and Genetic: Poster II 
Hematology Disease Topics & Pathways: 
Clinically Relevant 

Sunday, December 12, 2021, 6:00 PM-8:00 PM 

Maher Albitar, MD^1*, Hong Zhang, PhD^1*, Andre H. Goy, MD, MS^2*, Zijun Xu-Monette, PhD^3*, Govind Bhagat, M.D.⁴, Carlo Visco, MD^5*, Alexandar Tzankov, MD^6*, Xiaosheng Fang^3*, Feng Zhu^7*, Karen Dybkaer, PhD, MSC^8*, April Chiu, MD^9*, Wayne Tam, MD, PhD¹⁰, Youli Zu, MD, PhD^11*, Eric D. Hsi, MD¹², F. B. Hagemeister, MD¹³, Jooryung Huh^14*, Maurilio Ponzoni, MD¹⁵, Andrés J M Ferreri, MD¹⁶, Michael Moller^17*, Benjamin M Parsons, DO¹⁸, Joannes H.J.M. Van Krieken, PhD, MD^19*, Miguel Angel Piris^20*, Jane N. Winter, MD²¹, Yong Li^22*, Bing Xu, MD, PhD^23* and Ken H. Young²⁴ 

4.  

3463 Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms 

Program: Oral and Poster Abstracts 
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III 
Hematology Disease Topics & Pathways: 
Translational Research 

Monday, December 13, 2021, 6:00 PM-8:00 PM 

Maher Albitar, MD^1*, Andrew Ip, MD, MSc², Andre H. Goy, MD^3*, Jeffrey Justin Estella, BS, MS^1*, Ivan De Dios, BS^1*, Wanlong Ma^1*, Andrew L. Pecora, MD^4*, Jamie Koprivnikar, MD^5* and James K McCloskey, MD⁵